{"title":"Rebound Hypoxemia in Mechanically Ventilated Patients With COVID-19 Completing a Standard 10-Day Course of Corticosteroid Therapy.","authors":"Rahul Costa-Pinto, Hannah Rotherham, Zachary O'Brien, Padeepa Perera, Vicky Chen, Christopher Massarany, Brett Xu, Rinaldo Bellomo","doi":"10.1089/respcare.12494","DOIUrl":null,"url":null,"abstract":"<p><p><b>Background:</b> Rebound hypoxemia may occur after cessation of corticosteroid therapy for COVID-19 pneumonitis. We aimed to determine the incidence of this phenomenon in mechanically ventilated patients with COVID-19 completing corticosteroid therapy. <b>Methods:</b> We conducted a retrospective observational cohort study across 2 tertiary ICUs from September to December 2021. We included all adult patients receiving invasive mechanical ventilation on completion of a 10-day course of dexamethasone for COVID pneumonitis. Our primary outcome was change in P<sub>aO<sub>2</sub></sub>/F<sub>IO<sub>2</sub></sub> ratio in the 7 days following cessation of dexamethasone. Secondary outcomes included duration of ventilation, frequency of corticosteroid recommencement, and mortality. <b>Results:</b> We studied 88 subjects. Median age was 61 years (interquartile range [IQR] 51-67), and median duration of mechanical ventilation was 14 days (IQR 11-26). On completion of dexamethasone, 62 subjects (70%) remained off corticosteroid therapy for the subsequent 7 days. Of these, 63% (<i>n =</i> 20) had a stable P<sub>aO<sub>2</sub></sub>/F<sub>IO<sub>2</sub></sub> ratio on day 7 (mean change 197 ± 42 mm Hg to 258 ± 83 mm Hg). Subjects who had a reduction in P<sub>aO<sub>2</sub></sub>/F<sub>IO<sub>2</sub></sub> ratio >20 mm Hg by day 7 (mean change 214 ± 68 mm Hg to 152 ± 78 mm Hg) were more likely to die in hospital (<i>P</i> < .001). These subjects had a higher C-reactive protein level at time of steroid cessation (204 ± 87 mg/L, <i>P</i> = .17), which remained persistently elevated (206 ± 89 mg/L, <i>P</i> = .01) on day 7. The 30% of subjects who recommenced steroids required a longer duration of ventilation (13.5 vs 24.5 d, <i>P</i> = .002) but showed no differences in ICU mortality (19% vs 27%, <i>P</i> = .43). <b>Conclusions:</b> Rebound hypoxemia and steroid recommencement were common occurrences in mechanically ventilated subjects with COVID-19. Rebound hypoxemia was associated with higher mortality. Steroid recommencement was associated with longer duration of mechanical ventilation but no significant difference in mortality.</p>","PeriodicalId":21125,"journal":{"name":"Respiratory care","volume":" ","pages":""},"PeriodicalIF":2.4000,"publicationDate":"2025-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Respiratory care","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1089/respcare.12494","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CRITICAL CARE MEDICINE","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Rebound hypoxemia may occur after cessation of corticosteroid therapy for COVID-19 pneumonitis. We aimed to determine the incidence of this phenomenon in mechanically ventilated patients with COVID-19 completing corticosteroid therapy. Methods: We conducted a retrospective observational cohort study across 2 tertiary ICUs from September to December 2021. We included all adult patients receiving invasive mechanical ventilation on completion of a 10-day course of dexamethasone for COVID pneumonitis. Our primary outcome was change in PaO2/FIO2 ratio in the 7 days following cessation of dexamethasone. Secondary outcomes included duration of ventilation, frequency of corticosteroid recommencement, and mortality. Results: We studied 88 subjects. Median age was 61 years (interquartile range [IQR] 51-67), and median duration of mechanical ventilation was 14 days (IQR 11-26). On completion of dexamethasone, 62 subjects (70%) remained off corticosteroid therapy for the subsequent 7 days. Of these, 63% (n = 20) had a stable PaO2/FIO2 ratio on day 7 (mean change 197 ± 42 mm Hg to 258 ± 83 mm Hg). Subjects who had a reduction in PaO2/FIO2 ratio >20 mm Hg by day 7 (mean change 214 ± 68 mm Hg to 152 ± 78 mm Hg) were more likely to die in hospital (P < .001). These subjects had a higher C-reactive protein level at time of steroid cessation (204 ± 87 mg/L, P = .17), which remained persistently elevated (206 ± 89 mg/L, P = .01) on day 7. The 30% of subjects who recommenced steroids required a longer duration of ventilation (13.5 vs 24.5 d, P = .002) but showed no differences in ICU mortality (19% vs 27%, P = .43). Conclusions: Rebound hypoxemia and steroid recommencement were common occurrences in mechanically ventilated subjects with COVID-19. Rebound hypoxemia was associated with higher mortality. Steroid recommencement was associated with longer duration of mechanical ventilation but no significant difference in mortality.
背景:COVID-19肺炎患者停止皮质类固醇治疗后可能出现反弹性低氧血症。我们的目的是确定在完成皮质类固醇治疗的机械通气的COVID-19患者中这种现象的发生率。方法:我们于2021年9月至12月对2个三级icu进行了回顾性观察队列研究。我们纳入了所有在完成10天地塞米松治疗COVID - 19肺炎疗程后接受有创机械通气的成年患者。我们的主要终点是停用地塞米松后7天内PaO2/FIO2比值的变化。次要结局包括通气持续时间、重新使用皮质类固醇的频率和死亡率。结果:研究对象88例。中位年龄为61岁(四分位间距[IQR] 51 ~ 67),中位机械通气持续时间为14天(IQR 11 ~ 26)。完成地塞米松治疗后,62名受试者(70%)在随后的7天内仍未使用皮质类固醇治疗。其中,63% (n = 20)在第7天PaO2/FIO2比率稳定(平均变化为197±42 mm Hg至258±83 mm Hg)。第7天PaO2/FIO2比值降低bbb20 mm Hg(平均变化214±68 mm Hg至152±78 mm Hg)的患者更容易在医院死亡(P < 0.001)。停用类固醇时c -反应蛋白水平较高(204±87 mg/L, P = 0.17),第7天仍持续升高(206±89 mg/L, P = 0.01)。30%重新使用类固醇的受试者需要更长的通气时间(13.5 vs 24.5 d, P = 0.002),但ICU死亡率没有差异(19% vs 27%, P = 0.43)。结论:在机械通气的COVID-19患者中,反弹性低氧血症和类固醇重新使用是常见的。反跳性低氧血症与较高的死亡率相关。类固醇重新使用与机械通气持续时间延长有关,但死亡率无显著差异。
期刊介绍:
RESPIRATORY CARE is the official monthly science journal of the American Association for Respiratory Care. It is indexed in PubMed and included in ISI''s Web of Science.